RLMD Relmada Therapeutics, Inc.

NASDAQ
$2.86

Relmada Therapeutics, Inc. (RLMD) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $0.12 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -39.3% since its last earnings release on November 12, 2026.

Relmada Therapeutics Beat Consensus Estimates
Thursday, November 12, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($0.12)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.41

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.